Kyverna Therapeutics, Inc. (KYTX)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch KYTX
See up to 3 months of KYTX. The 7-day demo opens the 1M and 3M ranges and puts KYTX on your watchlist.
Start 7-day demoLatest KYTX insider trades
About Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. files with the SEC under CIK 0001994702 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
KYTX Form 4 activity by transaction type, last 90 days
No Form 4 activity for KYTX in the last 90 days.
KYTX insider transactions (Form 4)
3419 Form 4 filings on record, the earliest from Oct 24, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ian T. Clark | Grant or award | Common Stock | 5,093 footnote F1 | $0.00 | - | |
| Ian T. Clark | Grant or award | Stock Option (right to buy) | 20,582 | $0.00 | - | |
| ||||||
| Fred E. Cohen | Grant or award | Common Stock | 5,093 footnote F1 | $0.00 | - | |
| Fred E. Cohen | Grant or award | Stock Option (right to buy) | 20,582 | $0.00 | - | |
| ||||||
| Beth C. Seidenberg | Grant or award | Common Stock | 5,093 footnote F1 | $0.00 | - | |
| Beth C. Seidenberg | Grant or award | Stock Option (right to buy) | 20,582 | $0.00 | - | |
| ||||||
 Christi Shaw - Officer | Tax withholding / forfeiture | Common Stock | 4,194 footnote F1 | $8.59 | $36K | |
| ||||||
| Mert Aktar | Grant or award | Common Stock | 5,093 footnote F1 | $0.00 | - | |
| Mert Aktar | Grant or award | Stock Option (right to buy) | 20,582 | $0.00 | - | |
| ||||||
| Gregory S. Martini - Officer | Grant or award | Stock Option (right to buy) | 325,000 | $0.00 | - | |
 Nadia Dac - Officer | Grant or award | Stock Option (right to buy) | 300,000 | $0.00 | - | |
| Marc Grasso - Officer | Grant or award | Common Stock | 10,000 footnote F1 | $0.00 | - | |
| Marc Grasso - Officer | Grant or award | Stock Option (right to buy) | 65,000 | $0.00 | - | |
| ||||||
 Warner Weston Biddle - Officer | Grant or award | Common Stock | 58,000 footnote F1 | $0.00 | - | |
| Warner Weston Biddle - Officer | Grant or award | Stock Option (right to buy) | 350,000 | $0.00 | - | |
| ||||||
| Naji Gehchan - Officer | Grant or award | Common Stock | 18,000 footnote F1 | $0.00 | - | |
| Naji Gehchan - Officer | Grant or award | Stock Option (right to buy) | 105,000 | $0.00 | - | |
| ||||||
| Andrew Craig Miller | Grant or award | Stock Option (right to buy) | 42,945 | $0.00 | - | |
| Andrew Craig Miller | Grant or award | Common Stock | 11,006 footnote F1 | $0.00 | - | |
| ||||||
| Sravan Kumar Emany | Grant or award | Common Stock | 11,006 footnote F1 | $0.00 | - | |
| Sravan Kumar Emany | Grant or award | Stock Option (right to buy) | 42,945 | $0.00 | - | |
| ||||||
| Mayobanex Pujols - Officer | Grant or award | Stock Option (right to buy) | 300,000 | $0.00 | - | |
| Christi Shaw - Officer | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| Christi Shaw - Officer | Grant or award | Common Stock | 24,301 footnote F2 | $0.00 | - | |
| Christi Shaw - Officer | Grant or award | Stock Option (right to buy) | 185,000 | $0.00 | - | |
| ||||||
| Karen Marie Walker - Officer | Option exercise | Common Stock | 23,998 | $4.83 | $116K | |
| Karen Marie Walker - Officer | Open-market sale | Common Stock | 23,998 | $12.20 | $293K | |
| Karen Marie Walker - Officer | Option exercise | Stock option (right to buy) | 23,998 | $0.00 | - | |
| Marc Grasso - Officer | Grant or award | Stock Option (right to buy) | 450,000 | $0.00 | - | |
| Daniel K. Spiegelman | Grant or award | Common Stock | 16,634 | $0.00 | - | |
| Daniel K. Spiegelman | Grant or award | Stock Option (right to buy) | 65,351 | $0.00 | - | |
| Beth C. Seidenberg | Grant or award | Common Stock | 16,634 | $0.00 | - | |
| Beth C. Seidenberg | Grant or award | Stock Option (right to buy) | 65,351 | $0.00 | - | |
| Mert Aktar | Grant or award | Stock Option (right to buy) | 87,741 | $0.00 | - | |
Item 7.01, 9.01
Item 2.02, 9.01
Item 1.01, 7.01, 9.01
Item 1.01, 9.01
KYTX insider trading FAQ
What is the latest insider trade for KYTX?
Kyverna Therapeutics, Inc. (KYTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-29. The full record for KYTX runs to 19 Form 4 filings, the earliest from 2024-10-24. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying KYTX stock?
No insider purchases of KYTX were filed in the last 90 days.
How many insiders are selling KYTX stock?
No insider sales of KYTX were filed in the last 90 days. 1 sale is on record for this company.
Where can I see KYTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects KYTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Ian T. Clark view on EDGAR
- - Fred E. Cohen view on EDGAR
- - Beth C. Seidenberg view on EDGAR
- - Christi Shaw view on EDGAR
- - Mert Aktar view on EDGAR
- - Gregory S. Martini view on EDGAR
- - Nadia Dac view on EDGAR
- - Marc Grasso view on EDGAR
- - Warner Weston Biddle view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where KYTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow KYTX with a 7-day demo
- KYTX on your watchlist
- Every KYTX Form 4 filing on record
- Up to 3 months of KYTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
